Prime Medicine
PRME
167 hedge funds and large institutions have $512M invested in Prime Medicine in 2025 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 63 increasing their positions, 31 reducing their positions, and 7 closing their positions.
657% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 7
253% more capital invested
Capital invested by funds: $145M → $512M (+$367M)
103% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 31
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
42% more call options, than puts
Call options by funds: $8.69M | Put options by funds: $6.12M
38% more funds holding
Funds holding: 121 → 167 (+46)
23.92% more ownership
Funds ownership: 44.7% → 68.62% (+24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$16.3M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$12.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$12.2M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.2M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$8.07M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.78M |
| 3 |
FAM
Fred Alger Management
New York
|
-$1.06M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$916K |
| 5 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
-$513K |
PRME Hedge Fund Activity: Q3 2025 in Review
167 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q3 2025, worth a combined $512M — up 253% from $145M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new PRME positions and 7 closed out — a net gain of 46 holders — while 63 added to existing stakes and 31 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $16.3M. The largest seller was Redmile Group, cutting an estimated $8.07M.
- 167 institutional investors held Prime Medicine (PRME) as of Q3 2025, up from 121 in Q2 2025.
- Funds reported $512M of Prime Medicine stock for Q3 2025, up 253% quarter-over-quarter.
- 53 funds opened new Prime Medicine positions in Q3 2025 and 7 closed out, a net change of +46 holders.
- The largest Prime Medicine buyer in Q3 2025 was Farallon Capital Management, an estimated $16.3M added.
- The largest Prime Medicine seller in Q3 2025 was Redmile Group, an estimated $8.07M sold.
Based on aggregated 13F filings for Q3 2025.